Novo Nordisk A/S

NOVO-B · Nasdaq Copenhagen · Healthcare

248.75DKK −0.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −25.9%

Performance

1 month

−17.5%

1 year

−25.9%

3 years, per year

−25.0%

5 years, per year

−2.8%

Largest fall, 3 years

−76.7%

Below the peak now

−73.8%

Volatility, 1 year

47.1%

Return with dividends reinvested.

Key figures

P/E

9.3

P/B

4.9

Dividend yield

4.7%

Return on equity

+52.6%

Net margin

+35.3%

Market value

166.2 bn USD

Quality, value and trend

Where Novo Nordisk stands against every Nordic stock today. 100 is best.

Quality93

Profitability and a sound balance sheet over time. Better than 93% of Nordic stocks.

Value43

The price measured against earnings, assets and cash flow. Better than 43% of Nordic stocks.

Trend35

The price development over the past year. Better than 35% of Nordic stocks.

Combined59

Quality, value and trend together. Better than 59% of Nordic stocks.

About Novo Nordisk

Novo Nordisk A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 66,500 employees.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis